Quest Diagnostics (DGX) to Release Earnings on Tuesday

Quest Diagnostics (NYSE:DGX) is anticipated to post its Q2 2025 quarterly earnings results before the market opens on Tuesday, July 22nd. Analysts expect Quest Diagnostics to post earnings of $2.56 per share and revenue of $2.73 billion for the quarter.

Quest Diagnostics (NYSE:DGX) last posted its quarterly earnings results on Tuesday, April 22nd. The medical research company reported $2.21 EPS for the quarter, topping analysts’ consensus estimates of $2.15 by $0.06. The firm had revenue of $2.65 billion for the quarter, compared to analysts’ expectations of $2.63 billion. Quest Diagnostics had a net margin of 8.81% and a return on equity of 15.11%. On average, analysts expect Quest Diagnostics to post $10 EPS for the current fiscal year and $10 EPS for the next fiscal year.

Quest Diagnostics Stock Performance

DGX stock opened at $168.34 on Tuesday. The firm has a market cap of $18.79 billion, a price-to-earnings ratio of 21.28, a PEG ratio of 2.35 and a beta of 0.49. The firm has a 50-day simple moving average of $175.69 and a two-hundred day simple moving average of $168.75. Quest Diagnostics has a one year low of $137.71 and a one year high of $182.38. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.31 and a current ratio of 1.44.

Quest Diagnostics Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, July 21st. Stockholders of record on Monday, July 7th will be paid a dividend of $0.80 per share. The ex-dividend date of this dividend is Monday, July 7th. This represents a $3.20 dividend on an annualized basis and a dividend yield of 1.90%. Quest Diagnostics’s payout ratio is 40.46%.

Insider Buying and Selling

In other Quest Diagnostics news, SVP Mark E. Delaney sold 874 shares of Quest Diagnostics stock in a transaction on Monday, May 12th. The shares were sold at an average price of $175.72, for a total value of $153,579.28. Following the completion of the transaction, the senior vice president owned 8,372 shares of the company’s stock, valued at $1,471,127.84. The trade was a 9.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. 8.16% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Quest Diagnostics

A hedge fund recently bought a new stake in Quest Diagnostics stock. Brighton Jones LLC bought a new stake in shares of Quest Diagnostics Incorporated (NYSE:DGX) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 2,144 shares of the medical research company’s stock, valued at approximately $323,000. Hedge funds and other institutional investors own 88.06% of the company’s stock.

Wall Street Analyst Weigh In

DGX has been the topic of several analyst reports. Piper Sandler lifted their price target on Quest Diagnostics from $180.00 to $200.00 and gave the stock a “neutral” rating in a report on Monday, April 28th. Redburn Partners set a $195.00 price target on Quest Diagnostics in a report on Wednesday, April 2nd. Robert W. Baird lifted their price target on Quest Diagnostics from $191.00 to $194.00 and gave the stock an “outperform” rating in a report on Wednesday, April 23rd. Truist Financial lifted their price target on Quest Diagnostics from $182.00 to $190.00 and gave the stock a “hold” rating in a report on Wednesday, April 23rd. Finally, Evercore ISI lifted their price target on Quest Diagnostics from $175.00 to $180.00 and gave the stock an “in-line” rating in a report on Wednesday, April 23rd. Eight investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Quest Diagnostics currently has a consensus rating of “Moderate Buy” and a consensus price target of $185.73.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.